Zobrazeno 1 - 10
of 383
pro vyhledávání: '"M. J. Edelman"'
Autor:
Al-Odat, Omar S.1,2 (AUTHOR) jonnalagadda@rowan.edu, Nelson, Emily1,2 (AUTHOR) nelson52@students.rowan.edu, Budak-Alpdogan, Tulin3 (AUTHOR) budak-alpdogan-tulin@cooperhealth.edu, Jonnalagadda, Subash C.2 (AUTHOR), Desai, Dhimant4 (AUTHOR) ddesai@pennstatehealth.psu.edu, Pandey, Manoj K.1 (AUTHOR) pandey@rowan.edu
Publikováno v:
Cancers. Jul2024, Vol. 16 Issue 13, p2381. 21p.
Autor:
Li, Caiming1,2 (AUTHOR), Kang, Nan3 (AUTHOR), Ye, Shun4 (AUTHOR), Huang, Weihang5 (AUTHOR), Wang, Xia6 (AUTHOR), Wang, Cheng7 (AUTHOR), Li, Yuchen1,8 (AUTHOR), Liu, Yan‐Fei1,9 (AUTHOR), Lan, Ying1 (AUTHOR), Ma, Liang10 (AUTHOR), Zhao, Yuhang10 (AUTHOR), Han, Yong10 (AUTHOR), Fu, Jun10 (AUTHOR), Shen, Danhua3 (AUTHOR), Dong, Lianhua6 (AUTHOR) donglh@nim.ac.cn, Du, Wenbin1,2,11 (AUTHOR) wenbin@im.ac.cn
Publikováno v:
Advanced Science. 6/5/2024, Vol. 11 Issue 21, p1-12. 12p.
Publikováno v:
Cancer. 92(1)
The objective of this Phase II study was to evaluate the concept of sequential chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma (NSCLC) by the administration of carboplatin plus gemcitabine followed by of paclitaxe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f21e4def77905c2cd8ac086e63f90ec5
https://pubmed.ncbi.nlm.nih.gov/12173351
https://pubmed.ncbi.nlm.nih.gov/12173351
Publikováno v:
Oncology (Williston Park, N.Y.). 15(3 Suppl 6)
Combinations of gemcitabine (Gemzar) with cisplatin (Platinol) are among the most active new chemotherapy regimens developed for advanced non-small-cell lung cancer. Carboplatin (Paraplatin) is a platinum analog devoid of many of the nonhematologic t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9834a330195c4c3e22cbdcc96a93b8f2
https://pubmed.ncbi.nlm.nih.gov/11301843
https://pubmed.ncbi.nlm.nih.gov/11301843
Autor:
M J, Edelman
Publikováno v:
Chest surgery clinics of North America. 10(3)
Several new agents developed in the past decade have demonstrated activity in esophageal cancer. No single agent or combination of agents has been compared in a randomized study with the current standard, albeit limited, treatment of cisplatin and 5-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::17dcb70d1693d9e3d620a8a9fa20c909
https://pubmed.ncbi.nlm.nih.gov/10967757
https://pubmed.ncbi.nlm.nih.gov/10967757
Publikováno v:
Oncology (Williston Park, N.Y.). 14(7 Suppl 4)
Platinum compounds, either cisplatin (Platinol) or carboplatin (Paraplatin), in combination with a number of new chemotherapeutic agents, have demonstrated improved response or survival compared to cisplatin alone or older platinum-based regimens. Ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c2e7e5992550a52382e936939bb49c87
https://pubmed.ncbi.nlm.nih.gov/10960942
https://pubmed.ncbi.nlm.nih.gov/10960942
Autor:
P C, Mack, D R, Gandara, C, Bowen, M J, Edelman, T, Paglieroni, J B, Schnier, E P, Gelmann, P H, Gumerlock
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(9)
7-Hydroxystaurosporine (UCN-01), a protein kinase inhibitor in clinical development, demonstrates potent antineoplastic activity. To determine whether specific genetic abnormalities would modulate the response to UCN-01, a model of human non-small ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43e9c9fdcc83c3add6989cde6ec5722f
https://pubmed.ncbi.nlm.nih.gov/10499638
https://pubmed.ncbi.nlm.nih.gov/10499638
Autor:
M J, Edelman, D R, Gandara, F J, Meyers, R, Ishii, M, O'Mahony, M, Uhrich, I, Lauder, J, Houston, D W, Gietzen
Publikováno v:
Cancer. 86(4)
Imbalanced amino acid diets in animals rapidly produce anorexia and weight loss. Blockade of type 3 serotonergic receptors (5HT(3)) can ameliorate anorexia in this animal model. Imbalanced plasma amino acid levels also have been documented in both an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6b4db019f233992ce520ca1fe40077bf
https://pubmed.ncbi.nlm.nih.gov/10440697
https://pubmed.ncbi.nlm.nih.gov/10440697
Publikováno v:
Seminars in oncology. 26(3 Suppl 10)
In the first-line treatment of advanced non-small cell lung cancer (NSCLC), phase II trials of single-agent docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) at a dose of 100 mg/m2 every 3 weeks have reported encouraging results, with an ove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4dde13d7ccebb3766d7762ea27271ed2
https://pubmed.ncbi.nlm.nih.gov/10437743
https://pubmed.ncbi.nlm.nih.gov/10437743
Autor:
M J, Edelman
Publikováno v:
The oncologist. 4(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c8323ac6bd82ce41295a313b59dedbb7
https://pubmed.ncbi.nlm.nih.gov/10394591
https://pubmed.ncbi.nlm.nih.gov/10394591